tiprankstipranks
Advertisement
Advertisement
Larimar Therapeutics price target lowered to $5 from $7 at Baird
PremiumThe FlyLarimar Therapeutics price target lowered to $5 from $7 at Baird
11d ago
Larimar Therapeutics selloff a buying opportunity, says Citi
Premium
The Fly
Larimar Therapeutics selloff a buying opportunity, says Citi
11d ago
Larimar Therapeutics: Buy Rating on Nomlabofusp’s Robust FA Efficacy and De-Risked Regulatory Pathway
Premium
Ratings
Larimar Therapeutics: Buy Rating on Nomlabofusp’s Robust FA Efficacy and De-Risked Regulatory Pathway
12d ago
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp
PremiumThe FlyLarimar Therapeutics submits first module of rolling BLA for nomlabofusp
12d ago
Larimar Therapeutics: Buy Rating Reaffirmed as Nomlabofusp Regulatory Catalysts and Data Updates Support Steady $14 Price Target and 280% Upside
Premium
Ratings
Larimar Therapeutics: Buy Rating Reaffirmed as Nomlabofusp Regulatory Catalysts and Data Updates Support Steady $14 Price Target and 280% Upside
12d ago
Lamb Weston, FedEx, BioNTech, Zscaler, Larimar Trending With Analysts
Premium
Weekend Updates
Lamb Weston, FedEx, BioNTech, Zscaler, Larimar Trending With Analysts
1M ago
Larimar Therapeutics price target lowered to $12 from $13 at Wedbush
PremiumThe FlyLarimar Therapeutics price target lowered to $12 from $13 at Wedbush
2M ago
Larimar Therapeutics Reaffirmed as Buy on Nomlabofusp Progress and Regulatory De-Risking; $25 Price Target Maintained
Premium
Ratings
Larimar Therapeutics Reaffirmed as Buy on Nomlabofusp Progress and Regulatory De-Risking; $25 Price Target Maintained
2M ago
Myles Minter Reiterates Buy on Larimar as Nomlabofusp Advances Toward 2026 BLA and Potential First Disease‑Modifying FA Therapy by 2027
Premium
Ratings
Myles Minter Reiterates Buy on Larimar as Nomlabofusp Advances Toward 2026 BLA and Potential First Disease‑Modifying FA Therapy by 2027
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―